Positive 24 month Clinical Data for Aorfix™ Stent Graft
London, UK, 11 September 2006 - Lombard Medical Technologies PLC (“Lombard Medical”) today announces positive clinical data on its Aorfix™ stent graft, presented on Saturday 9th September at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting in Rome.
Professor Trojanowska of the Department of Interventional Radiology at the University School of Medicine, Lublin, Poland reported data on 18 patients who had reached twenty-four month follow-up with 100% of cases showing freedom from abdominal aortic aneurysm (AAA)-related mortality, aneurysm rupture, stent migration, stent fracture and device related endoleaks. Furthermore, she reported that there were no device related clinical treatments in any of the patients and that a decrease in aneurysm diameter was measured in 83 per cent of the cases.
Aorfix™ has been used in more than 170 patients worldwide, and Aorfix™ devices have now been in situ in some patients for over four years. A number of these patients have aortic angulations greater than 60 degrees.
Alistair Taylor, Chairman of Lombard Medical, said:
“We have presented excellent 24 month clinical data on our Aorfix™ stent graft in a small mixed group of anatomies. In terms of freedom from device related endoleak the results are superior to those reported by competitor products in the more simple anatomies. Furthermore the level of device migration is comparable to the market leader and superior to all other products."
“The clinical data further supports Aorfix™ as a highly effective stent graft for the treatment of AAA.”
Enquiries:
Lombard Medical Technologies PLC Tel: 01235 750 800
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer
Financial Dynamics Tel: 020 7831 3113
David Yates / John Gilbert
Notes to editors
Lombard Medical Technologies is a medical devices company developing stent grafts and other medical products for use in the treatment of vascular disease. The Company’s lead product, Aorfix™, is a stent graft for the treatment of aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Abdominal and thoracic aortic aneurysms are the 13th largest cause of death in the US and the market is estimated to be worth approximately US$2 billion by 2010. Aorfix™ is currently being commercialised in the EU, with US clinical trials expected to commence during 2006. The Company also has a research programme running with Amgen and the University of Sheffield to develop a drug eluting stent with a new drug and polymer combination to treat coronary stent restinosis.
Lombard Medical has recently successfully completed its initial public offering on AIM and was admitted to listing in December 2005, raising £23.9 million, net of expenses. The Company, based in Oxfordshire & Yorkshire, currently employs 85 people.
Further background on the Company can be found at www.lombardmedical.com.